Initial Public Offering
6,000,000 shares of common stock
in an offering underwritten by
J.P. Morgan, Goldman Sachs & Co., LLC. and Cowen
Frequency Therapeutics is a clinical stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Through our venture capital affiliates, we invested in the Company’s first round of financing and continued to support the Company in each subsequent financing round through its IPO.
Comments are closed.